# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-002606
Filing Date
2025-04-03
Accepted
2025-04-03 17:17:38
Documents
20
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formpre14a.htm iXBRL | PRE 14A | 696565
2 |  | pre14a_001.jpg | GRAPHIC | 38906
3 |  | pre14a_002.jpg | GRAPHIC | 37472
4 |  | pre14a_004.jpg | GRAPHIC | 28349
5 |  | proxy_001.jpg | GRAPHIC | 954588
6 |  | proxy_002.jpg | GRAPHIC | 509709
| Complete submission text file | 0001641172-25-002606.txt |  | 5064014

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL SCHEMA FILE | erna-20241231.xsd | EX-101.SCH | 6167
8 | XBRL DEFINITION FILE | erna-20241231_def.xml | EX-101.DEF | 10690
9 | XBRL LABEL FILE | erna-20241231_lab.xml | EX-101.LAB | 65718
10 | XBRL PRESENTATION FILE | erna-20241231_pre.xml | EX-101.PRE | 45362
22 | EXTRACTED XBRL INSTANCE DOCUMENT | formpre14a_htm.xml | XML | 160975

Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-11460 | Film No.: 25810742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)